{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T07:59:22Z","timestamp":1722844762936},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer Yakuhin, Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00535-016-1173-5","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T15:56:23Z","timestamp":1456847783000},"page":"1011-1021","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study"],"prefix":"10.1007","volume":"51","author":[{"given":"Shuichi","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sunaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyo","family":"Inuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiwamu","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"issue":"5 Suppl 1","key":"1173_CR1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch FX, Ribes J, D\u00edaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5\u201316.","journal-title":"Gastroenterology"},{"key":"1173_CR2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907\u201317.","journal-title":"Lancet"},{"key":"1173_CR3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1173_CR4","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. http:\/\/globocan.iarc.fr . Accessed 8 June 2015."},{"key":"1173_CR5","unstructured":"Center for Cancer Control and Information Services. Latest cancer statistics. http:\/\/ganjoho.jp\/reg_stat\/statistics\/dl\/index.html#incidence . Accessed 27 Nov 2015."},{"key":"1173_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000367727","volume":"4","author":"M Kudo","year":"2015","unstructured":"Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4:39\u201350.","journal-title":"Liver Cancer"},{"key":"1173_CR7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208\u201336.","journal-title":"Hepatology."},{"key":"1173_CR8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1365-2036.2006.02932.x","volume":"23","author":"PM Lopez","year":"2006","unstructured":"Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma\u2013an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535\u201347.","journal-title":"Aliment Pharmacol Ther"},{"key":"1173_CR9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","volume":"130","author":"DF Calvisi","year":"2006","unstructured":"Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC. Gastroenterology. 2006;130:1117\u201328.","journal-title":"Gastroenterology"},{"key":"1173_CR10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/hep.510270409","volume":"27","author":"Y Ito","year":"1998","unstructured":"Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases\/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27:951\u20138.","journal-title":"Hepatology"},{"key":"1173_CR11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","volume":"41","author":"D Semela","year":"2004","unstructured":"Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864\u201380.","journal-title":"J Hepatol"},{"key":"1173_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-2006-960171","volume":"27","author":"A Villanueva","year":"2007","unstructured":"Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55\u201376.","journal-title":"Semin Liver Dis"},{"key":"1173_CR13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1173_CR14","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"1173_CR15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","volume":"98","author":"F Carlomagno","year":"2006","unstructured":"Carlomagno F, Anaganti S, Guida T, et al. BAY43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326\u201334.","journal-title":"J Natl Cancer Inst"},{"key":"1173_CR16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821\u20139.","journal-title":"J Hepatol"},{"key":"1173_CR17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1173_CR18","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","volume":"48","author":"AL Cheng","year":"2012","unstructured":"Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48:1452\u201365.","journal-title":"Eur J Cancer"},{"key":"1173_CR19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol."},{"key":"1173_CR20","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067\u201375.","journal-title":"J Clin Oncol"},{"key":"1173_CR21","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517\u201324.","journal-title":"J Clin Oncol"},{"key":"1173_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99:159\u201365.","journal-title":"Cancer Sci"},{"key":"1173_CR23","volume-title":"Nexavar\u00ae tablets 200\u00a0Mg (Nonproprietary Nane: Sorafenib Tosylate Tablets) specific drug use investigation interim report (unresectable hepatocellular carcinoma)","author":"Post-Marketing Surveillance Manager","year":"2012","unstructured":"Post-Marketing Surveillance Manager. Nexavar\u00ae tablets 200\u00a0Mg (Nonproprietary Nane: Sorafenib Tosylate Tablets) specific drug use investigation interim report (unresectable hepatocellular carcinoma). Osaka: Bayer Yakuhin Ltd; 2012."},{"key":"1173_CR24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jjco\/hyv099","volume":"45","author":"H Akaza","year":"2015","unstructured":"Akaza H, Oya M, Iijima M, et al. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. Jpn J Clin Oncol. 2015;45:953\u201362.","journal-title":"Jpn J Clin Oncol"},{"key":"1173_CR25","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","volume":"23","author":"G Dranitsaris","year":"2012","unstructured":"Dranitsaris G, Vincent MD, Yu J, et al. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol. 2012;23:2103\u20138.","journal-title":"Ann Oncol"},{"key":"1173_CR26","unstructured":"Lu SN, Lin SM, Chen PT, et al. Randomized investigation of prophylactic corticosteroid versus non-corticosteroid ointment for reducing cutaneous toxicity in Taiwanese patients receiving sorafenib for hepatocellular carcinoma. In: Poster presented at: 23rd Conference of the Asia Pacific Association for the Study of Liver; June 6\u20139, 2013; Singapore. Poster P183."},{"key":"1173_CR27","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:894\u2013900.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1173_CR28","doi-asserted-by":"publisher","first-page":"e0138776","DOI":"10.1371\/journal.pone.0138776","volume":"10","author":"T Kuzuya","year":"2015","unstructured":"Kuzuya T, Ishigami M, Ishizu Y, et al. Early clinical response after 2 weeks of sorafenib therapy predicts outcomes and anti-tumor response in patients with advanced hepatocellular carcinoma. PLoS One. 2015;10(9):e0138776. doi: 10.1371\/journal.pone.0138776 .","journal-title":"PLoS One"},{"key":"1173_CR29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/hepr.12354","volume":"45","author":"M Morimoto","year":"2015","unstructured":"Morimoto M, Numata K, Kondo M, et al. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis. Hepatol Res. 2015;45:279\u201387.","journal-title":"Hepatol Res"},{"key":"1173_CR30","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3892\/ijo.2014.2654","volume":"45","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Osaki Y, Endo M, et al. Comparison of standard-dose and half-dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: a propensity score matching analysis. Int J Oncol. 2014;45:2295\u2013302.","journal-title":"Int J Oncol"},{"key":"1173_CR31","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","volume":"54","author":"M Iavarone","year":"2011","unstructured":"Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54:2055\u201363.","journal-title":"Hepatology"},{"key":"1173_CR32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","volume":"33","author":"S Ogasawara","year":"2015","unstructured":"Ogasawara S, Chiba T, Ooka Y, et al. Sorafenib treatment in child-pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs. 2015;33:729\u201339.","journal-title":"Invest New Drugs"},{"issue":"Suppl 2","key":"1173_CR33","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0168-8278(15)30585-7","volume":"62","author":"JP Bronowicki","year":"2015","unstructured":"Bronowicki JP, Kudo M, Lencioni R, et al. GIDEON: a retrospective analysis of prognostic factors for survival. J Hepatol. 2015;62(Suppl 2):S451\u20132.","journal-title":"J Hepatol"},{"key":"1173_CR34","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1111\/hepr.12480","volume":"45","author":"H Takeda","year":"2015","unstructured":"Takeda H, Nishikawa H, Osaki Y, et al. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res. 2015;45:E130\u201340.","journal-title":"Hepatol Res"},{"issue":"Suppl 1","key":"1173_CR35","first-page":"89 S86","volume":"4","author":"AL Cheng","year":"2015","unstructured":"Cheng AL, Llovet JM, Meinhardt G, et al. Retrospective pooled analysis of advanced HCC patients in SHARP and AP randomized clinical trials. Liver Cancer. 2015;4(Suppl 1):89 S86.","journal-title":"Liver Cancer."},{"key":"1173_CR36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","volume":"61","author":"M Reig","year":"2014","unstructured":"Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318\u201324.","journal-title":"J Hepatol"},{"key":"1173_CR37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7150\/jca.9257","volume":"5","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Takeda H, Tsuchiya K, et al. Sorafenib therapy for BCLC stage B\/C hepatocellular carcinoma; clinical outcome and safety in aged patients: a multicenter study in Japan. J Cancer. 2014;5:499\u2013509.","journal-title":"J Cancer."},{"key":"1173_CR38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1872-034X.2012.00981.x","volume":"42","author":"S Kaneko","year":"2012","unstructured":"Kaneko S, Furuse J, Kudo M, et al. Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. Hepatol Res. 2012;42:523\u201342.","journal-title":"Hepatol Res."}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-016-1173-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1173-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:17:07Z","timestamp":1718389027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-016-1173-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1173-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}